Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund lowered its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 7.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,325 shares of the biotechnology company’s stock after selling 184 shares during the period. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Axon Enterprise were worth $727,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new position in Axon Enterprise during the 4th quarter worth $26,000. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise during the 1st quarter worth $31,000. First PREMIER Bank purchased a new position in Axon Enterprise during the 1st quarter worth $33,000. Key Financial Inc raised its position in Axon Enterprise by 367.6% during the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after buying an additional 125 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC purchased a new position in Axon Enterprise during the 1st quarter worth $41,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Down 0.1 %

AXON traded down $0.22 during trading on Friday, hitting $310.59. 347,882 shares of the company’s stock were exchanged, compared to its average volume of 449,251. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $329.87. The stock has a 50 day moving average price of $294.49 and a 200 day moving average price of $292.33. The firm has a market cap of $23.44 billion, a P/E ratio of 90.82, a price-to-earnings-growth ratio of 7.00 and a beta of 0.95.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business had revenue of $460.74 million for the quarter, compared to analysts’ expectations of $441.57 million. During the same period in the previous year, the company posted $0.51 earnings per share. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise, Inc. will post 2.35 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the sale, the director now directly owns 1,607 shares of the company’s stock, valued at $498,282.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the sale, the director now directly owns 1,607 shares of the company’s stock, valued at $498,282.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the sale, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,447 shares of company stock valued at $27,684,677. Corporate insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Craig Hallum increased their price target on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Barclays increased their price target on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday, May 8th. JPMorgan Chase & Co. increased their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a report on Thursday, April 11th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $375.00 price target on shares of Axon Enterprise in a report on Tuesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $342.54.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.